Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
CCK-A
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "CCK-A" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
1
Target:
Research Areas:
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
1
1 Cited Publications
Target:
Research Areas:
Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
Cat. No.: HY-P1096
CAS No.: 130408-77-4
Target:
Research Areas:
Research Areas:
Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .
Target:
Research Areas:
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.
Cat. No.: HY-U00387
CAS No.: 137004-80-9
Target:
Research Areas:
CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binging IC50 of 340 nM.
Cat. No.: HY-123434
CAS No.: 181941-32-2
Target:
Research Areas:
PD-149164 is a potent agonist of cholecystokinin B (CCK-B) receptor, with IC50 values of 0.083 nM and 75 nM in binding assay to CCK-B and CCK-A .
Cat. No.: HY-U00363
CAS No.: 167820-10-2
Synonyms: FK-480
Target:
Research Areas:
CHEMBL333994 (FK-480) is a potent and orally active Cholecystokinin A receptor (CCK-A receptor) antagonist, with an IC50 of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .
Cat. No.: HY-U00062
CAS No.: 141374-81-4
Target:
Research Areas:
Tarazepide is a potent and specific CCK-A receptor antagonist.
Cat. No.: HY-111918
CAS No.: 127902-33-4
Target:
Research Areas:
A71378 is a selectivity CCK-A receptor agonist the IC50 values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC50 = 0.16 nM) and ileal muscle contraction (EC50 = 3.7 nM) .
Cat. No.: HY-118665
CAS No.: 152885-49-9
Target:
Research Areas:
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg) .
Cat. No.: HY-RS02074
Target:
Research Areas:
CCKAR Human Pre-designed siRNA Set A contains three designed siRNAs for CCKAR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-123182
CAS No.: 140677-01-6
Target:
Research Areas:
PD-140548 is a selective cholecystokinin (CCKA) receptor antagonist. PD-140548 can be used in schizophrenia research .
Cat. No.: HY-169065
CAS No.: 558638-15-6
Antibacterial agent 241 is a histidine kinase (HK) inhibitor, with IC50 values of 14 μM and 238 μM for CckA and PhoQ, respectively. Antibacterial agent 241 shows moderate antibacterial activity against E. coli DC2, Bacillus cereus, and Bacillus subtilis, with a MIC range of 12-74 μg/mL .
Cat. No.: HY-119127
CAS No.: 176915-07-4
Target:
Research Areas:
TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCKA receptors (IC50=1.2 nM) than to rat brain CCKB receptors (IC50=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .
Cat. No.: HY-U00363A
CAS No.: 126149-42-6
Synonyms: (rac)-FK-480
Target:
Research Areas:
(rac)-CHEMBL333994 is the racemate of CHEMBL333994 (HY-U00363). CHEMBL333994 is a potent and orally active Cholecystokinin A receptor (CCK-A receptor) antagonist, with an IC50 of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .
Cat. No.: HY-129516
CAS No.: 131449-37-1
Target:
Research Areas:
A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC50 of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor .
Cat. No.: HY-103354A
CAS No.: 85068-56-0
Target:
Research Areas:
Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
Cat. No.: HY-103354R
CAS No.: 99247-33-3
Research Areas:
Proglumide (sodium) (Standard) is the analytical standard of Proglumide (sodium). This product is intended for research and analytical applications. Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
